A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells

Cancer Letters

Volumn 371, Issue 2, 2016, Pages 240-250

  Jhaveri, Niyati ^a   Agasse, Fabienne ^a   Armstrong, Don ^b   Peng, Lilei ^c   Commins, Deborah ^a   Wang, Weijun ^a   Rosenstein Sisson, Rachel ^a   Vaikari, Vijaya Pooja ^a   Santiago, Shayane V ^a   Santos, Tiago ^a   Chen, Ligang ^c   Schönthal, Axel H ^a   Chen, Thomas C ^a   Hofman, Florence M ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Luzhou Medical University   (China)

Author keywords

DNA damage; Glioblastoma; Glioma cancer stem cells; Mesenchymal; NEO212; Proneural; TMZ resistance

Indexed keywords

ANTINEOPLASTIC AGENT; PERILLYL ALCOHOL; TEMOZOLOMIDE; TEMOZOLOMIDE PERILLYL ALCOHOL CONJUGATE; UNCLASSIFIED DRUG; ALKYLATING AGENT; DACARBAZINE; NEO212; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER STEM CELL; CELL POPULATION; CONTROLLED STUDY; CYTOTOXICITY; DNA STRAND BREAKAGE; DRUG CONJUGATION; DRUG EFFICACY; DRUG MECHANISM; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN NEOPLASMS; COMPARATIVE STUDY; DOSE RESPONSE; DOUBLE STRANDED DNA BREAK; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; GLIOMA; MESENCHYMAL STROMA CELL; METABOLISM; NEURAL STEM CELL; NONOBESE DIABETIC MOUSE; PATHOLOGY; SCID MOUSE; TIME FACTOR; TUMOR CELL CULTURE; TUMOR INVASION; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; DACARBAZINE; DNA BREAKS, DOUBLE-STRANDED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; MALE; MESENCHYMAL STROMAL CELLS; MICE, INBRED NOD; MICE, SCID; NEOPLASM INVASIVENESS; NEOPLASTIC STEM CELLS; NEURAL STEM CELLS; TIME FACTORS; TUMOR BURDEN; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84962019102     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.11.040     Document Type: Article

References (38)

1. Ostrom Q.T., Gittleman H., Farah P., Ondracek A., Chen Y., Wolinsky Y., et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol 2013, 15(Suppl. 2):ii1-ii56.
2. Stupp R., Hegi M.E., Mason W.P., van den Bent M.J., Taphoorn M.J., Janzer R.C., et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009, 10:459-466.
3. Chen J., Li Y., Yu T.S., McKay R.M., Burns D.K., Kernie S.G., et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 2012, 488:522-526.
4. Lapidot T., Sirard C., Vormoor J., Murdoch B., Hoang T., Caceres-Cortes J., et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367:645-648.
5. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med 1997, 3:730-737.
6. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:3983-3988.
7. Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., et al. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
8. Galli R., Binda E., Orfanelli U., Cipelletti B., Gritti A., De Vitis S., et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004, 64:7011-7021.
9. Yuan X., Curtin J., Xiong Y., Liu G., Waschsmann-Hogiu S., Farkas D.L., et al. Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene 2004, 23:9392-9400.
10. Vescovi A.L., Galli R., Reynolds B.A. Brain tumour stem cells. Nat. Rev. Cancer 2006, 6:425-436.
11. Gangemi R.M., Griffero F., Marubbi D., Perera M., Capra M.C., Malatesta P., et al. SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity. Stem Cells 2009, 27:40-48.
12. Lee J., Kotliarova S., Kotliarov Y., Li A., Su Q., Donin N.M., et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006, 9:391-403.
13. Wakimoto H., Mohapatra G., Kanai R., Curry W.T., Yip S., Nitta M., et al. Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells. Neuro Oncol 2012, 14:132-144.
14. Pollard S.M., Yoshikawa K., Clarke I.D., Danovi D., Stricker S., Russell R., et al. Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell 2009, 4:568-580.
15. Blough M.D., Westgate M.R., Beauchamp D., Kelly J.J., Stechishin O., Ramirez A.L., et al. Sensitivity to temozolomide in brain tumor initiating cells. Neuro Oncol 2010, 12:756-760.
16. Beier D., Schriefer B., Brawanski K., Hau P., Weis J., Schulz J.B., et al. Efficacy of clinically relevant temozolomide dosing schemes in glioblastoma cancer stem cell lines. J. Neurooncol 2012, 109:45-52.
17. Verhaak R.G., Hoadley K.A., Purdom E., Wang V., Qi Y., Wilkerson M.D., et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17:98-110.
18. Lottaz C., Beier D., Meyer K., Kumar P., Hermann A., Schwarz J., et al. Transcriptional profiles of CD133+ and CD133- glioblastoma-derived cancer stem cell lines suggest different cells of origin. Cancer Res 2010, 70:2030-2040.
19. Cho H.Y., Wang W., Jhaveri N., Lee D.J., Sharma N., Dubeau L., et al. NEO212, temozolomide conjugated to perillyl alcohol, is a novel drug for effective treatment of a broad range of temozolomide-resistant gliomas. Mol. Cancer Ther 2014, 13:2004-2017.
20. Chen T.C., Cho H.Y., Wang W., Nguyen J., Jhaveri N., Rosenstein-Sisson R., et al. A novel temozolomide analog, NEO212, with enhanced activity against MGMT-positive melanoma in vitro and in vivo. Cancer Lett 2015, 358:144-151.
21. Chen T.C., Cho H.Y., Wang W., Barath M., Sharma N., Hofman F.M., et al. A novel temozolomide-perillyl alcohol conjugate exhibits superior activity against breast cancer cells in vitro and intracranial triple-negative tumor growth in vivo. Mol. Cancer Ther 2014, 13:1181-1193.
22. Virrey J.J., Golden E.B., Sivakumar W., Wang W., Pen L., Schonthal A.H., et al. Glioma-associated endothelial cells are chemoresistant to temozolomide. J. Neurooncol 2009, 95:13-22.
23. Neman J., Termini J., Wilczynski S., Vaidehi N., Choy C., Kowolik C.M., et al. Human breast cancer metastases to the brain display GABAergic properties in the neural niche. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:984-989.
24. R Core Team R: A Language and Environment for Statistical Computing 2013, R Foundation for Statistical Computing, Vienna, Austria.
25. Gautier L., Cope L., Bolstad B.M., Irizarry R.A. Affy - analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 2004, 20:307-315.
26. Yang Y.H., Dudoit S., Luu P., Lin D.M., Peng V., Ngai J., et al. Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res 2002, 30:e15.
27. Kardosh A., Soriano N., Liu Y.T., Uddin J., Petasis N.A., Hofman F.M., et al. Multitarget inhibition of drug-resistant multiple myeloma cell lines by dimethyl-celecoxib (DMC), a non-COX-2 inhibitory analog of celecoxib. Blood 2005, 106:4330-4338.
28. De Bacco F., Casanova E., Medico E., Pellegatta S., Orzan F., Albano R., et al. The MET oncogene is a functional marker of a glioblastoma stem cell subtype. Cancer Res 2012, 72:4537-4550.
29. Johannessen T.C., Bjerkvig R. Molecular mechanisms of temozolomide resistance in glioblastoma multiforme. Expert Rev. Anticancer Ther 2012, 12:635-642.
30. Collins A.R. The comet assay for DNA damage and repair: principles, applications, and limitations. Mol. Biotechnol 2004, 26:249-261.
31. Kuo L.J., Yang L.X. Gamma-H2AX - a novel biomarker for DNA double-strand breaks. In Vivo 2008, 22:305-309.
32. Zhou B.B., Bartek J. Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat. Rev. Cancer 2004, 4:216-225.
33. Ostermann S., Csajka C., Buclin T., Leyvraz S., Lejeune F., Decosterd L.A., et al. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin. Cancer Res 2004, 10:3728-3736.
34. Brada M., Judson I., Beale P., Moore S., Reidenberg P., Statkevich P., et al. Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br. J. Cancer 1999, 81:1022-1030.
35. Fu D., Calvo J.A., Samson L.D. Balancing repair and tolerance of DNA damage caused by alkylating agents. Nat. Rev. Cancer 2012, 12:104-120.
36. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.
37. Phillips H.S., Kharbanda S., Chen R., Forrest W.F., Soriano R.H., Wu T.D., et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006, 9:157-173.
38. Chirasani S.R., Sternjak A., Wend P., Momma S., Campos B., Herrmann I.M., et al. Bone morphogenetic protein-7 release from endogenous neural precursor cells suppresses the tumourigenicity of stem-like glioblastoma cells. Brain 2010, 133:1961-1972.